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9ABSTRACT
Oculomotor and other neurotologic dysfunction in migraine is evident, but results are not con-
sistent. About 40% of familial hemiplegic migraine type 1 (FHM1) patients show permanent 
cerebellar signs, whereas familial hemiplegic migraine type 2 (FHM2) patients show normal 
neurologic status interictally. Episodic ataxia type 2 (EA2) patients can develop permanent 
cerebellar signs in the course of the disease and show pronounced nystagmus interictally be-
fore any other cerebellar signs are detectable. In this study, we examined quantitatively ocu-
lomotor function and other neurotologic ﬁ ndings in episodic ataxia type 2 (EA2) with a novel 
CACNA1A splice site mutation, in the common types of migraine, and in familial hemiplegic 
migraine type 2 (FHM2).
The neurotologic results for common types of migraine (36 patients and 43 controls) indicate 
that oculomotor dysfunction originates from the vestibulocerebellum for both migraine with 
aura (MA) and migraine without aura (MO). In video-oculography (VOG), abnormal nystag-
mus occurred in migraine subjects, but not in controls. Additionally, in migraine, increased 
body sway in posturography and decreased accuracy in saccadic tests suggested subclinical 
vestibulocerebellar dysfunction.
To our knowledge, quantitative oculomotor tests have not previously been performed on FHM2 
patients. They usually show normal neurologic status interictally, as was the case with our 
FHM2 patients. However, the oculomotor tests on nine FHM2 patients suggested subclinical 
changes in postural control and in oculomotor function.
EA2 patients have well-characterized eye-movement abnormalities. They localize to the ves-
tibulocerebellum with gaze-evoked, rebound, or downbeat nystagmus. We studied the effect of 
acetazolamide on baseline oculomotor and postural dysfunction in three EA2 family members 
on acetazolamide. Recordings were made with and without medication. After a wash-out pe-
riod, we showed that with acetazolamide, interictal oculomotor and postural function in these 
patients improved.
Proton (1H) magnetic resonance spectroscopy (MRS) of the brain in EA2 has shown high lactate 
peaks, but no changes in N-acetylaspartate (NAA) or in other 1H MRS metabolite ratios. We 
studied nine mostly nonataxic EA2 family members with a speciﬁ c CACNA1A mutation by 1H 
MRS to evaluate metabolite changes in the cerebellar hemispheres, the vermis, and the thala-
mus. These EA2 patients, showing no atrophy in the cerebellum in MRI, showed decreased total 
creatine (tCr) in the cerebellar hemispheres and in the vermis. These results suggest cerebellar 
Purkinje cell dysfunction in EA2, possibly reﬂ ecting early signs of CACNA1A dysfunction.
In summary, this study suggests that MA and MO share similar abnormalities in interictal neu-
rotologic dysfunction that may reﬂ ect central vestibular and cerebellar etiology. The results for 
FHM2 with subclinical abnormalities in neurotologic testing shared similar features with MA 
and MO as to defective oculomotor function. EA2 patients showed improved oculomotor func-
tion from baseline dysfunction with acetazolamide. Signiﬁ cantly decreased cerebellar tCr may 
reﬂ ect, in EA2, the ﬁ rst signs of intrinsic dysfunction of a CACNA1A mutation.
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REVIEW OF THE LITERATURE
1. Clinical characteristics of migraine and episodic ataxia type 2
1.1. Migraine with and without aura
Migraine is a common neurological disorder, which affects up to 6% of men and 18% of 
women in the general population (Lipton and Stewart, 1998, Launer et al., 1999). Anyone 
can have an occasional migraine attack, if the triggering factors are strong enough, but mi-
graine attacks must be recurrent before one is deﬁ ned as a migraine patient. Common types 
of migraine include migraine with typical aura (MA) and migraine without aura (MO) 
according to International Headache Society criteria (IHS) (International Headache, 1988, 
Headache Classiﬁ cation Subcommittee of the International Headache, 2004). Migraine at-
tacks are characterized by a unilateral throbbing headache of moderate to severe intensity, 
accompanied by nausea or vomiting, or photophobia and phonophobia. Physical exertion 
typically worsens the symptoms. About 20% of migraineurs have aura symptoms (MA) 
preceding a headache which usually starts within an hour after the aura has occurred. In 
MA, a visual aura with fortiﬁ cation spectrum is the most common aura type, with hemi-
sensoric symptoms next in frequency. Less frequent are speech disturbances and unilateral 
weakness. Migraine attacks usually last from 4 to 72 hours.
Common symptoms among migraineurs are vertigo and dizziness (Baloh, 1997). Recently, 
migrainous vertigo was evaluated to be the most common cause of spontaneous recurrent 
vertigo (Neuhauser and Lempert, 2004), but is not presently included in the IHS criteria 
(Headache Classiﬁ cation Subcommittee of the International Headache, 2004). Migrainous 
vertigo presents with attacks of spontaneous or positional vertigo that last from seconds to 
days (Neuhauser et al., 2001). At least one of the following migrainous symptoms should 
occur at least in two vertiginous attacks: photophobia, phonophobia, migrainous head-
ache, or visual or other auras. Migraine can cause positional vertigo as well, mimicking 
benign paroxysmal positional vertigo (BPPV). Compared to BPPV, migrainous vertigo 
presents shorter-lasting episodes, frequent recurrences, manifestation early in life, migrain-
ous symptoms during positional vertigo, and atypical positional nystagmus (von Brevern 
et al., 2004).
BPPV and Meniere’s disease occur often among migraineurs, but the pathophysiologi-
cal link is as yet unknown. Migraine presents three times as often in patients with BPPV 
of unknown cause as in those with BPPV secondary to trauma (Ishiyama et al., 2000). 
The lifetime prevalence of migraine is increased in patients with Meniere’s disease. Up 
to 45% of patients with Meniere’s disease experience migrainous symptoms (migrainous 
headache, photophobia, aura symptoms), which suggests a pathophysiologic link between 
these diseases. On the other hand, current diagnostic criteria may not differentiate between 
Meniere’s disease and migrainous vertigo with sufﬁ cient accuracy (Radtke et al., 2002).
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1.2. Familial hemiplegic migraine (FHM)
Familial hemiplegic migraine (FHM) is a rare, autosomal dominant form of MA that in-
cludes motor weakness and at least one ﬁ rst- or second-degree relative with similar symp-
toms (International Headache, 1988, Headache Classiﬁ cation Subcommittee of the Inter-
national Headache, 2004). The aura can be prolonged for several days or weeks and outlast 
the headache phase. Usually the aura symptoms follow each other in succession, with 
visual disturbances, hemiparesthesia, and dysarthria or dysphasia often preceding and ac-
companying hemiparesis (Ducros et al., 2001, Gardner et al., 1997). Basilar-type migraine 
symptoms (e.g., vertigo, loss of balance, diplopia, bilateral visual symptoms switching 
from one side to the other, and drop attacks, as well as bilateral paresis or paresthesia or 
both) often occur last in the aura succession. FHM and basilar migraine show overlap-
ping clinical phenotypes (Haan et al., 1995); basilar migraine symptoms are present in 
up to 68% of FHM patients (Thomsen et al., 2002), but some FHM patients have atypi-
cal attacks with confusion, decreased consciousness, fever, aseptic meningeal reaction, or 
seizures (Ducros et al., 1997, Gardner et al., 1997, Echenne et al., 1999, Kors et al., 2001, 
Marconi et al., 2003), with minor head trauma at times provoking attacks (Gardner et al., 
1997, Ducros et al., 2001, Vanmolkot et al., 2003, Kors et al., 2001). Cerebral or coronary 
angiography can also trigger an attack (Ducros et al., 2001). Interestingly, some FHM pa-
tients may present with the common types of migraine attacks, as well (Ducros et al., 2001, 
Thomsen et al., 2002). This supports the hypothesis that FHM may be part of the migraine 
spectrum and can be used as a model to study the complex genetics and pathophysiology 
of the common types of migraine. 
FHM has been divided into type 1 (FHM1) and type 2 (FHM2) on a genetic basis. Clini-
cally it is difﬁ cult to separate the disorders. Cerebellar signs divide FHM1 families into 
pure FHM families (80% of the families) and FHM with cerebellar signs (20%) (Ducros 
et al., 2001). FHM2 families have shown no cerebellar signs (Marconi et al., 2003) except 
for one family of Italian origin (Spadaro et al., 2004). A few sporadic hemiplegic migraine 
patients also show cerebellar signs (Ducros et al., 1999, Vahedi et al., 2000). In FHM1, 
minor head trauma can cause cerebral edema or even fatal coma (Kors et al., 2001). Mild 
to moderate mental retardation has occurred in two Italian FHM2 families (Marconi et al., 
2003) and in a British FHM1 family (Kors et al., 2003b). 
1.3. Episodic ataxia type 2 (EA2)
Two forms of familial episodic ataxia exist: episodic ataxia type 1 with periodical ataxia 
and interictal myokymia (EA1), while episodic ataxia type 2 (EA2) shows bouts of vertigo, 
ataxia, dysarthria, nystagmus, nausea, vomiting, and fatigue. EA2 attacks commonly last 
from half an hour to two hours, whereas the bouts in EA1 are brief, lasting only minutes 
(Baloh and Winder, 1991, Ophoff et al., 1996). As part of the attack spectrum, about half 
the EA2 patients have migraine headache, and some present with hemiplegia (Baloh et al., 
1997, Jen et al., 2001, Jen et al., 2004). Some have reported epilepsy (Jouvenceau et al., 
2001, Jen et al., 2004). Attacks are most often triggered by physical exercise or emotional 
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stress. Sometimes heat, coffee, small amounts of alcohol, or bright sunshine predispose to 
attacks (Subramony et al., 2003). The onset of the episodes is usually before age 20, where-
as possible progressive cerebellar ataxia usually appears much later (Baloh et al., 1997, 
Harding, 1993). Spinocerebellar ataxia type 6 (SCA6), a late onset dominantly inherited 
ataxia syndrome, has clinical features — progressive cerebellar ataxia, oculomotor dys-
function, and ictal headaches or nausea (Ying et al., 2001, Sinke et al., 2001) — that may 
overlap with those of EA2 and FHM. SCA6 may present, although rarely, with episodes 
of dizziness and ataxia before permanent cerebellar signs. EA2 and SCA6 may reﬂ ect the 
same disorder with high phenotypic variability (Jen et al., 1998, Jodice et al., 1997).
In EA2 patients, neurological examination and MRI can range from normal ﬁ ndings to 
cerebellar ataxia plus atrophy (Baloh and Winder, 1991, Baloh et al., 1997). Moreover, 
variation in clinical phenotype appears between and within families (Van Den Maagden-
berg et al., 2002). 
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2. Genetics and pathophysiology of migraine and EA2 
2.1. Genetics of migraine
Family, twin, and genetic studies have shown that migraine etiology is complex, with mul-
tiple interacting genetic and environmetal factors (Russell and Olesen, 1995, Ulrich et al., 
1999, Gervil et al., 1999). For example, a large population-based study shows that ﬁ rst-de-
gree relatives of probands with MA have a relative risk of 3.8 for developing MA, whereas 
their spouses have no increased risk (Russell and Olesen, 1995). For MO, the relative risk 
for ﬁ rst-degree relatives is lower (1.9). The complex genetics of migraine has hampered 
gene identiﬁ cation in the common types of migraine with conﬂ icting results (Table 1). 
Association studies, such as those of the dopaminergic system (Del Zompo et al., 1998, 
Peroutka et al., 1997, Maude et al., 2001, Shepherd et al., 2002), the serotonergic system 
(Erdal et al., 2001, Burnet et al., 1997, Kotani et al., 2002), mitochondria (Takeshima et al., 
2001), the endothelial system (Tzourio et al., 2001), and homocysteine-related genes (Kara 
et al., 2003), are examples of areas of interest in migraine genetics.
Table 1. Results of linkage studies in common types of migraine.
Chromosome Population/ number of families Disease
19p13
No linkage to 19p13
May et al., 1995
Nyholt et al., 1998
Jones et al., 2001
Terwindt et al., 2001 
Hovatta et al., 1994
Noble-Topham et al., 2002
Brugnoni et al., 2002
Wieser et al., 2003
Kaunisto et al., 2004
German/ 28 families
Australian/ 4 families
US/ 16 families
Dutch/ 36 families
Finnish/ 4 families
Canadian/ 64 families
Italian/ 12 families
German/ 143 unrelated 
patients
Finnish/72 families
MA
1q31 Lea et al., 2002 Australian/ one family MA and MO
4q24 Wessman et al., 2002 Finnish/ 50 families MA
4q21 Björnsson et al., 2003 Icelandic/ 103 families MO
6p12.2-p21.1 Carlsson et al., 2002 Swedish/ one family MO and MA
11q24 Cader et al., 2003 Canadian/ 43 families MA
14q21.2-q22.3 Soragna et al., 2003 Italian/ one family MO
Xq24-q28 Nyholt et al., 2000 Australian/ 2 families MA and MO
MA, migraine with aura; MO, migraine without aura
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2.2. Genetics of FHM 
FHM is inherited as an autosomal dominant trait and has turned out to be genetically het-
erogeneous (Ducros et al., 1997, Carrera et al., 1999). Nowadays, FHM is divided into two 
subtypes based on genetic background: Type 1 (FHM1) with mutations in the CACNA1A 
gene in chromosome 19p13 (Ophoff et al., 1996, Ducros et al., 2001) and type 2 (FHM2) 
with mutations in the ATP1A2 gene on chromosome 1q23 (De Fusco et al., 2003, Van-
molkot et al., 2003). Some families are not linked to these loci, however, which indicates 
that more loci for FHM must exist (Ducros et al., 1997).
FHM1
In 1996 Ophoff et al. found a missense mutation in the CACNA1A of chromosome 19p13 
from four FHM families. CACNA1A encodes alpha 1A subunits of voltage-gated P/Q-type 
(Cav2.1) calcium channels in neurons, with an especially abundant expression in Purkinje 
cells of the cerebellum (Mori et al., 1991) (Figure 1). After 1996, at least 14 CACNA1A 
missense mutations were identiﬁ ed in 35 FHM families (Carrera et al., 1999, Ducros et al., 
2001, Wada et al., 2002, Takahashi et al., 2002, Alonso et al., 2003, Kors et al., 2003b). 
T666M mutation of the CACNA1A has been the most frequent mutation associated with 17 
FHM families (Ducros et al., 2001, Takahashi et al., 2002, Kors et al., 2003b). Kors et al. 
(2003b) described the clinical picture of ﬁ ve unrelated FHM families with a T666M muta-
tion. They found remarkable clinical heterogeneity among the families: Three of the fami-
lies showed cerebellar ataxia, one family showed attacks with confusion without hemipa-
resis, and another family, progressive cognitive dysfunction. About 20% of FHM1 patients 
present with cerebellar ataxia and cerebellar atrophy (Ducros et al., 2001).
CACNA1A mutations have been found in six sporadic hemiplegic migraine patients, as 
well (Carrera et al., 1999, Ducros et al., 2001, Terwindt et al., 2002, Kors et al., 2003a), 
most of them with cerebellar signs. However, in a study of Terwindt et al., (2002), most of 
these patients who were screened (25 of 27 patients) displayed no CACNA1A mutations.
FHM:                    FHM + Ataxia:
FHM
FHM with cerebellar signs
EA2
EA2 in a Finnish family
Extracellular
Intracellular
Domain I II III IV
N
C
CA
G
Figure 1. Structure of the alpha1A calcium channel subunit with some mutations indicated.
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FHM2
DeFusco et al. (2003) were the ﬁ rst to report two ATP1A2 missense mutations in chromo-
some 1q23 to cosegregate with FHM2. These were soon followed by Valmolkot et al. 
(2003) with a report of two novel missense mutations in the ATP1A2 in two families with 
FHM. Interestingly, one of their families cosegregated partially with benign familial infan-
tile convulsions. ATP1A2 encodes the alpha2 subunit of the Na+, K+-ATPase, which is ex-
pressed mostly in the astrocytes (Moseley et al., 2003). FHM shows incomplete penetrance 
in both FHM1 and FHM2 (Ducros et al., 1995, 2001), possibly with FHM2 presenting 
lower penetrance than FHM1 (Ducros et al., 1997).
2.3. Genetic background of EA2
Episodic ataxia type 1 and type 2 are each inherited as an autosomal dominant trait, EA1 
with mutations in a brain potassium channel (KCNA1) located on chromosome 12p, and 
EA2 with mutations in the CACNA1A on chromosome 19p13.
CACNA1A mutations show remarkable genotype-phenotype correlation complexity (Kors 
et al., 2002, Jen and Geschwind, 2001). Currently at least 34 different mutations in the 
CACNA1A gene have been identiﬁ ed in 26 EA2 families and 11 sporadic cases (Ophoff et 
al., 1996, Denier et al., 1999, Yue et al., 1998, Jen et al., 1999, Scoggan et al., 2001, Jen et 
al., 2001, Van Den Maagdenberg et al., 2002, Matsuyama et al., 2003, Subramony et al., 
2003, Jen et al., 2004). Early data associated CACNA1A missense mutations with FHM, 
and nonsense or splice site mutations with EA2. However, missense mutations (Friend et 
al., 1999, Denier et al., 2001, Guida et al., 2001, Jen et al., 2001, Van Den Maagdenberg 
et al., 2002, Jen et al., 2004), a deletion of three nucleotides (Denier et al., 1999), and a 
CAG repeat expansion (Jodice et al., 1997) have also caused EA2. A CAG repeat expan-
sion usually causes SCA6, a late-onset ataxia (Zhuchenko et al., 1997), but a CACNA1A 
missense mutation has also been identiﬁ ed in a family with a SCA6 phenotype (with epi-
sodic features) (Yue et al., 1997). EA2 mutation carriers show highly variable penetrance 
and expression of the disorder (Denier et al., 1999). Furthermore, as more EA2 families 
have nowadays been identiﬁ ed, evidence shows that the type of mutation or the mutation 
location in the CACNA1A does not predict the clinical phenotype (Jen et al., 2004). Antici-
pation, i.e., onset of disease as being earlier and symptoms being worse in generations to 
come, has not been reported in EA2 families (Baloh et al., 1997, Van Den Maagdenberg et 
al., 2002, Subramony et al., 2003), except in one study (Teh et al., 1995).
2.4. Migraine mechanisms
Substantial knowledge exists about migraine pathophysiology once the attack has started, 
but what is not known is why and how the attack actually begins (Ferrari, 1998, Kors et al., 
2003a, Silberstein, 2004). The aura is, according to the current view, caused by ”cortical 
spreading depression” (CSD) (Leao, 1944, Lauritzen, 1994). This is a depolarization wave 
that propagates across the cortex at 2 to 3-mm/min followed by a failure of brain-ion ho-
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meostasis, efﬂ ux of excitatory amino acids from nerve cells, enhanced energy metabolism 
(Lauritzen, 1994), and transient increases in cortical blood ﬂ ow followed by sustained ﬂ ow 
decreases (Bolay et al., 2002). In migraine headache pathophysiology, the trigeminovascu-
lar system is pivotal (Figure 2). The activation of the trigeminal nucleus caudalis and the 
trigeminal afferent ﬁ bers that innervate large cerebral vessels, pial vessels, large venous 
sinuses, and dura mater causes perivascular release of powerful vasoactive neuropeptides. 
This leads to vasodilatation, neurogenic inﬂ ammation, central transmission of pain infor-
mation, and headache (Ferrari, 1998, Kors et al., 2003a). Bolay et al. (Bolay et al., 2002) 
found, in an experimental study of CSD, a possible link between CSD and trigemino-
vascular activation in migraine with aura. Furthermore, in cats and rats, CSD induced a 
widespread release of nitric oxide (NO) (Read et al., 2000), which is a potent endogenous 
vasodilatator with multiple physiological actions. Increased cortical concentration of cy-
clic guanosine monophosphate (cGMP) (Read et al., 2001) and increased extracellular K+ 
(Van Den Maagdenberg et al., 2004) may facilitate CSD, as well.
During a migraine attack, more than 70% of migraine patients develop cutaneous allodynia 
(exaggerated skin sensitivity) (Burstein et al., 2000). This suggests a transient increase in 
the responsiveness (i.e., sensitization) of central pain neurons in addition to irritation of 
meningeal perivascular pain ﬁ bers.
Vascular risk factors such as smoking, high blood preassure, or use of oral contraceptives 
seem, in migraine patients, to have more than a multiplicative effect on risk for ischemic 
stroke (Chang et al., 1999). Migraine has been suggested to be an independent risk factor 
Figure 2. Trigeminovascular activation, where the 
activation of the trigeminal nucleus caudalis (TGN) 
and the trigeminal ﬁ bers cause perivascular release 
of vasoactive neuropeptides in large cerebral vessels 
and dura mater. This leads to vasodilatation, neu-
rogenic inﬂ ammation, central transmission of pain 
information, and headache. Cortical spreading de-
pression (CSD) may facilitate headache in migraine 
by releasing extracellular potassium ions (K+), hy-
drogen ions (H+), arachidonic acid (AA), nitric oxide 
(NO), etc. which in turn may depolarize perivascular 
trigeminal terminals that cause activation of the TGN 
in the brainstem. The activation of TGN caused by 
CSD produces vasodilatations of meningeal vessels 
through a pathway originating from the superior 
sagittal sinus (SSN) and reaching meningeal blood 
vessels via the sphenopalatine ganglion (SPG). The 
dashed lines between TGN, SSN, and regions gener-
ating the pain indicate that these connections are either unknown or have not been depicted. (Reprinted with 
permission of Nature’s copyright from Iadecola C: From CSD to headache: a long and winding road. Nat Med 
2002;8:110-112. http://www.nature.com/)
TGG = trigeminal ganglion; SPG = sphenopalatine ganglion; SSN = superior sagittal sinus
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for stroke in women of childbearing age (Tzourio et al., 1995, Carolei et al., 1996, Meri-
kangas et al., 1997), especially those with MA (Donaghy et al., 2002, Kruit et al., 2004). 
Possibly 20% to 40% of strokes in migrainous women develop directly from a migraine 
attack (Chang et al., 1999). Reports on patients with migrainous infarction suggest that 
the posterior circulation territory is most commonly affected (Hoekstra-van Dalen et al., 
1996, Milhaud et al., 2001). In addition, recent data on the prevalence of brain infarction 
and white matter lesions among patients with MA and MO conﬁ rm the vulnerability of the 
posterior circulation territory, especially the cerebellum of MA patients (Kruit et al., 2004). 
The risk for deep white matter lesions increases with attack frequency in women with MA 
or MO (Kruit et al., 2004).
The periaqueductal gray matter is at the center of the descending antinociceptive neuronal 
network. Iron homeostasis in this periaqueductal gray matter in patients with migraine 
with and without aura and chronic daily headache is progressively impaired. Thus the 
periaqueductal gray matter presents a possible important role in migraine attack genera-
tion, potentially by the dysfunction of the trigeminovascular nociceptive system (Welch et 
al., 2001).
5-Hydroxytryptamine
The metabolism of 5-hydroxytryptamine (5-HT) is disturbed in migraine patients with re-
duced systemic 5-HT levels interictally and raised levels during migraine attacks. This phe-
nomenon may reﬂ ect the failing self-defence mechanism (Ferrari et al., 1989). Acute anti-
migraine drugs, triptans, are 5-HT1B/1D receptor agonists with an ability to inhibit release 
of neuropeptides from trigeminal sensory nerve ﬁ bers (Goadsby, 2000). Triptan therapy 
provides complete pain relief for many migraine patients, but not for others. The probabil-
ity of consistent pain-free outcome increases if triptan therapy is timed to precede any signs 
of cutaneous allodynia (Burstein et al., 2004). The exact mechanism and site of action by 
which triptans abort migraine pain is unknown. In an animal model of intracranial pain, the 
analgesic action of sumatriptan appeared to exert its effects through presynaptic 5-HT1B/1D 
receptors in the dorsal horn, with blockage of synaptic transmission in the axon terminals 
of peripheral trigeminovascular neurons and in the cell bodies of central trigeminovascular 
neurons (Levy et al., 2004).
Interestingly, P-type neuronal calcium channels in vitro mediate 5-HT release (Codignola 
et al., 1993), adding a possible predisposition to migraine attacks in patients with these dys-
functioning channels. In rats, P/Q-, N-, and L-type voltage-gated calcium channels showed 
involvement in neurogenic trigeminovascular dural vasodilatation, which may imply in-
volvement in trigeminovascular nociception (Akerman et al., 2003).
Glyceryl trinitrate
Glyceryl trinitrate, a nitric oxide (NO) donor, can trigger a short-lived headache in healthy 
control individuals and in migraineurs, but in these patients it often also induces a delayed 
migraine attack (Olesen et al., 1994). The initial headache is thought to originate from 
direct action of the NO-cGMP pathway, while the delayed migraine is likely to result from 
trigeminovascular activation (Akerman et al., 2002). Increasing scientiﬁ c evidence sug-
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gests that NO plays an important role in primary headaches (Thomsen and Olesen, 2001). 
It has multiple physiological actions such as endothelium-dependent vasodilatation and 
neurogenic vasodilatation both of which may be mediated via perivascular nerves (Toda 
and Okamura, 1991, Toda et al., 1997), and may release relevant neurotransmitters such as 
calcitonin gene-related peptide (CGRP) from trigeminal ﬁ bers (Wei et al., 1992, Akerman 
et al., 2002, Strecker et al., 2002). Moreover, NO plays a role in neurotransmission in the 
central nervous system (CNS), which is of importance in pain perception (hyperalgesia) 
(Woolf and Thompson, 1991). 
Endothelin 1
In migraine patients, endothelin 1, a potent vasoconstictive peptide, has shown increased 
plasma levels ictally (Farkkila et al., 1992, Gallai et al., 1994, Kallela et al., 1998) and 
interictally (Gallai et al., 1994). The biological effects of endothelin 1 are mediated by 
endothelin type A and endothelin type B receptors. The former are expressed in vascular 
smooth muscle cells, and the receptor activation leads to vasoconstriction by endothelin 1 
(Arai et al., 1990). The endothelial system is complex, however, with a preceding phase of 
vasodilatation induced by the endothelin type B receptor activation before the endothelin 
type A receptor-mediated vasoconstriction takes place. Endothelin type A receptors medi-
ate an inhibitory action on NO synthesis in vascular smooth muscle cells by endothelin 1 
stimulation (Ikeda et al., 1997).
2.5. Functional studies and insights into the pathophysiology 
of FHM and EA2
2.5.1.   In vitro studies
FHM1
In vitro, some of the FHM1 mutations have produced gain-of-function, others loss-of-
function effects, or functional instability of human P/Q-type calcium channels (Hans et al., 
1999, Kraus et al., 1998, Kraus et al., 2000). In migraine with aura, single-ﬁ ber electromy-
ography (SFEMG) shows mild abnormalities in neuromuscular transmission (Ambrosini 
et al., 2001). After acetazolamide treatment for several weeks, the SFEMG shows abnor-
malities in migraine patients as being normalized (Ambrosini et al., 2003), which suggests 
that genetically modiﬁ ed Cav2.1 channels may be present in typical migraine as well. This 
conclusion has caused debate, because the possibility that Cav2.1 calcium channel dysfunc-
tion underlies typical migraine leads to ongoing controversy (van den Maagdenberg and 
Plomp, 2003). 
FHM2
Mutations in the ATP1A2 gene may result in a loss of function of the Na+,K+-ATPase 
pump, which may depolarize neurons. On the other hand, Na,K-ATPase may be kinetically 
altered but fully functional, and cause FHM2 (Segall et al., 2004). The neurons depolarize 
by impaired maintenance of Na+ and K+ gradients across the cell membrane (De Fusco et 
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al., 2003). Furthermore, the Na+,K+-ATPase pump alpha2 subunit is localized coinciden-
tally with the Na+,Ca2+ exchanger, which may eventually lead to an increase in intracellular 
Ca2+. Four isoforms of the catalytic alpha subunit have been identiﬁ ed to have a tissue- and 
developmental-speciﬁ c distribution (Lingrel et al., 2003). Their functional roles are as yet 
unknown, for the most part. Astrocytes that highly express ATP1A2 may impair K+ clear-
ance (Juhaszova and Blaustein, 1997). Consequently this, by increased extracellular K+, 
may facilitate CSD (Van Den Maagdenberg et al., 2004). Impaired Na+,K+-ATPase pumps 
may also cause an electrochemical Na+ gradient insufﬁ cient for astrocytes to remove syn-
aptic glutamate, which in part may modulate susceptibility and sustained migraine attacks 
(Moskowitz et al., 2004) (Figure 3). 
EA2
In EA2, missense and nonsense mutations in CACNA1A produce mutant channels with 
diminished whole-cell calcium channel activity in vitro due to loss of function (Jen et 
al., 2001, Wappl et al., 2002), with some of the mutations producing partially functional 
channels (Wappl et al., 2002). These altered biophysical properties may contribute to in 
vivo abnormal neuromuscular transmission, manifesting as weakness in the attack proﬁ le. 
Indeed, SFEMG shows jitter and blocking in EA2 patients (Jen et al., 2001), with signs 
of presynaptic failure of neurotransmission (Maselli et al., 2003). Neuromuscular trans-
mission in SFEMG in SCA6 patients is normal, suggesting that the nature of the SCA6 
mutations produces a distinctive phenotype at the level of neuromuscular transmission 
(Schelhaas et al., 2004).
Figure 3. Synaptic activity is 
coupled to glucose usage (up-
per panel). After depolariza-
tion, glutamate is released into 
the synaptic cleft regulated by 
Cav2.1 calcium channels that 
gate calcium inﬂ ux. Glutamate 
is taken up by astrocytes via 
speciﬁ c transporters that use 
the electrochemical gradient 
of Na+ as a driving force. The 
Na+ gradient is maintained 
by the activity of Na+, K+-
ATPase that removes sodium 
from inside cells. Glutamate 
(Glu) is converted into gluta-
mine (Gln) and subsequently 
released by astrocytes and 
taken up by neuronal termi-
nals, where it is enzymatically 
reconverted to Glu (lower 
panel). (Reprinted with permission from Magistretti PJ, Pellerin L, Douglas L, et al.. Energy on demand. Science; 
Vol 283 (5401):496-497,1999. Copyright 1999 AAAS)
Vcycle , ﬂ ux from glutamate to astrocytic glutamine; Vgln ,rate of glutamine cycle.
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2.5.2.   Mouse models
In order to investigate mechanisms of ataxia, dystonia, epilepsy, and migraine, at least four 
mutant mice models with spontaneous Cacna1a mutations have been developed: tottering, 
leaner, rolling, and rocker mice. Their phenotypes differ signiﬁ cantly in respect to ataxia 
severity, absence epilepsy and paroxysmal dyskinesias, cerebellar cell death, and ectopic 
dendritic spines on Purkinje cells (Zwingman et al., 2001). Ataxia is milder in tottering and 
rolling mice than in leaner mice (Mori et al., 2000). Signiﬁ cant cerebellar cell loss occurs 
in leaner and rolling mice, in contrast to rocker and tottering mice. The null mutant mice 
lack expression of the alpha1A subunit and thus have a complete loss of P-type channel 
function. These mice display severe progressive ataxia with premature death (Jun et al., 
1999). Leaner and tottering mice have absence epilepsy (Noebels, 1984, Fletcher et al., 
1996), whereas rocker mice have the ﬁ rst allele to present absence seizures without parox-
ysmal dyskinesias (Zwingman et al., 2001). 
Recently, a Cacna1a knockin transgenic mouse model was generated with the human 
R192Q mutation that causes pure FHM1 (Van Den Maagdenberg et al., 2004). The in-
vestigators found multiple gain-of-function effects with increased Cav2.1 current density 
in cerebellar neurons, enhanced neurotransmission at the neuromuscular junction, and a 
reduced threshold as well as increased velocity of CSD. They concluded that hyperexcit-
ability possibly causes the increased susceptibility to CSD and aura in migraine.
P/Q type calcium channels that are located on presynaptic terminals as well as on somato-
dendritic membranes regulate neurotransmitter release, postsynaptic calcium ﬂ uxes, and ex-
citability. The functional consequences of FHM1 mutations for the membrane properties of 
Cav2.1 are complex. Overall, all FHM1 mutations analyzed thus far display enhanced Ca
2+ 
inﬂ ux through single Cav2.1 channels for voltages lower than –10mV (single channel gain-
of-function phenotype). On the other hand, a loss of function was found in tranfected neurons 
and HEK293 cells due to a proposed reduced density of functional Cav2.1 channels in the 
membrane (Tottene et al., 2002). Van den Maagdenberg et al. (Van Den Maagdenberg et al., 
2004) later criticized this conclusion: Their data on the knockin mouse model suggest that 
transfected cells (either neurons or HEK293 cells) can reliably be used to study the effect of 
mutations on single channel function, but are unreliable in studying consequences of the ion 
channel mutation on the whole-cell current density.
Synaptic release of glutamate from cortical neurons depends primarily on the opening of 
Cav channels, whereas these channels are less signiﬁ cant in the regulation of gamma-amino 
butyric acid, GABA, release (Moskowitz et al., 2004). Accordingly, based on cortical micro-
dialysis, both tottering mice and the more severely affected allele leaner mice, have shown 
a decrease in depolarization-induced release of glutamate with almost no change in GABA. 
Tottering and leaner mice also showed a 10-fold resistance to CSD and, for leaner mice, also 
a slower velocity of CSD propagation (Ayata et al., 2000). These mice show an opposite elec-
trophysiological phenotype to that of the R192Q KI mutants. The lowered threshold for CSD 
in the homozygous R192Q KI mice may be due to cortical hyperexcitability resulting from 
increased glutamate release (Van Den Maagdenberg et al., 2004).
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Null mutant Atp1a2 mice die just after birth (Moseley et al., 2003, Ikeda et al., 2003, Lingrel 
et al., 2003). In these homozygous mice, Moseley et al. (Moseley et al., 2003) reports a prima-
ry neuronal defect in the brainstem. Heterozygous Atp1a2 mutant mice show hypercontractile 
hearts but, when compared to the wild type, no gross abnormalities (James et al., 1999).
2.6. Acetazolamide – a possible preventive medicine in EA2 and migraine
Acetazolamide is an inhibitor of the carbonic anhydrase enzyme, which catalyzes the fol-
lowing reaction:
CO2 + H20 ⇔ H2CO3 ⇔ H
+ + HCO-3
The exact preventive mechanism of acetazolamide in ion-channel disorder disease attacks 
is as yet unknown. However, pH changes under acetazolamide treatment are evident, with 
a possible stabilizing effect on dysfunctioning ion channels. By inhibiting carbonic an-
hydrase, acetazolamide causes metabolic acidosis with extracellular pCO2 increase and 
extracellular pH decrease. The carbonic anhydrase enzyme occurs in erythrocytes as well 
as in many other tissues such as the nervous system, kidney, gastric mucosa, and the eyes 
(Settakis et al., 2003). In the CNS, carbonic anhydrase occurs in the external surface of 
glial cells (Giacobini, 1962). 
Acetazolamide suppresses EA2 attacks effectively (Griggs et al., 1978, Baloh and Winder, 
1991), although it seems not to prevent progressive ataxia that may start later in life. There 
are few reports on acetazolamide responsiveness in FHM (Athwal and Lennox, 1996, Bat-
tistini et al., 1999, Kors et al., 2003b), on typical migraine (Vahedi et al., 2002, Haan et 
al., 2000), or on dominantly inherited migraine with episodic vertigo and essential tremor 
(Baloh et al., 1996). 
In prevention of typical migraine, one acetazolmide trial was prematurely halted because 
of the high number of withdrawals, primarily due to acetazolamide-induced multiple side-
effects (Vahedi et al., 2002). No obvious prophylactic beneﬁ cial effect of acetazolamide on 
migraine attacks had, however, appeared. On contrast to this, migraine aura status patients 
beneﬁ ted from acetazolamide, both in treatment of ongoing symptoms and in prevention of 
further migraine aura status periods (Haan et al., 2000).
3. The peripheral and central vestibular system
The inner ear is located within the petrous portion of the temporal bone inferior to the 
temporal lobe. The inner ear is made up of a bony labyrinth comprising a vestibular and 
a cochlear part. The cochlear part is further composed of membranous partitions of scala 
vestibule, scala media, and scala tympani. The scala media houses the organ of Corti that 
is responsible for hearing. The vestibular partitions consist of three semicircular canals and 
two otolith organs. The semicircular canals respond to angular acceleration of the head and 
the otoliths to linear acceleration. 
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Moreover, the maintenance of body equilibrium and posture involves multiple other re-
ceptor organs and neural centers in addition to the labyrinths. Visual and proprioceptive 
reﬂ exes must be integrated with vestibular reﬂ exes to ensure postural stability. The func-
tioning of the overall system is integrated in the brain stem and in the cerebellum by means 
of commissural, inferior olivary, and reverberating circuits.
3.1. The peripheral system
The vestibular system works in conjunction with the visual and proprioceptive systems to 
achieve gaze stability and postural stability. The peripheral vestibular system comprises the 
ear and the vestibular labyrinth with two otolith organs (the saccule and utricule) and a set 
of three semicircular canals (Figure 4). These form a coordinate system with the anterior 
and posterior canal in vertical positions almost orthogonal to each other, while the hori-
zontal canal makes a 30° angle with the horizontal plane. Each of the canals enlarges at its 
opening to the utriculus to form an ampulla. 
A crest-like septum, the crista, crosses each 
ampulla and consists of a sensory epithe-
lium of hair cells lying on a mound of con-
nective tissue. The endolymph movement 
within the canals stimulates these hair cells 
and thus transmits a biologic signal to an 
afferent neuron. 
The utriculus and the sacculus each have 
a sensory area with hair cells, the macule, 
which is covered by the gelatinous oto-
lithic membrane. This membrane contains 
superﬁ cial calcareous deposits, the otoco-
nia. Hair cells transmit signals to afferent 
neurons through the earth gravitation axis 
of the otoconia. The saccular and utricular 
macules sense linear acceleration, while 
the cristae of the three semicircular canals 
sense angular acceleration of the head. The labyrinthine blood circulation arises from the 
basilar artery: the anterior inferior cerebellar artery, labyrithine artery, common cochlear 
artery, anterior vestibular artery, and posterior vestibular artery, and their branches. 
3.2. The central system
The central vestibular system consists of vestibular nuclei in the brain stem, cerebellar-ves-
tibular interaction, vestibulospinal pathways, visual-vestibular interaction, and neck-ves-
tibular interaction (Figure 5). The vestibular nuclei are four: superior, lateral, medial, and 
inferior. Signals from thousands of primary afferent vestibular nerve ﬁ bers bombard the 
Utricle
Saccule
Semicircular
Canals
Figure 4. Vestibular labyrinth with two otolith organs 
(saccule and utricule) and semicircular canals.
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vestibular nuclei in a speciﬁ c orientation, depending on their organ of origin. After enter-
ing the brain stem, they divide into secondary ascending and descending branches each to 
reach its speciﬁ c part of the vestibular nuclei. In addition to labyrinthine afferents, afferent 
ﬁ bers from other systems (proprioceptive) and centers (especially the cerebellum) interact 
with signals from the vestibular organs. 
The vestibulo-ocular reﬂ exes — connections between the labyrinthine end-organs and eye 
muscles — involve the activity of many nuclei within the cerebellum and the brain stem 
and countless numbers of neurons that form disynaptic and polysynaptic excitatory and 
inhibitory pathways. The activity of a receptor organ produces activity in a group of motor 
neurons that coordinate eye-muscle contraction to compensate for a speciﬁ c head move-
ment and to maintain gaze stability. Alternate pathways also exist, with chains of interneu-
rons forming reverberating circuits. These interact and ﬁ ne-tune more speciﬁ c end-organ 
reﬂ exes. (Baloh, 2001)
3.3. Nystagmus
Nystagmus is a combination of nonvoluntary rhythmic slow and fast eye movements alter-
nating in opposite directions. The direction of the fast component deﬁ nes the direction of 
the nystagmus. Lesions of the labyrinth, of the vestibular nerve, of the vestibular nuclei, of 
cranial nerve III
cranial nerve IV
cranial nerve VI
Medial longitudinal
fasciculus (MLF)
spinal cord
Medial
vestibulospinal tract
Lateral
vestibulospinal tract
cerebellum
Labyrinth
Vestibular division of
cranial nerve VIII
Nuclei of:
Vestibular nuclei
Figure 5. Diagram of the central vestibular system with multiple interactions.
24
the vestibulo-ocular pathways, and of the cerebellum may cause nystagmus. The magni-
tude of induced nystagmus depends on the state of arousal and mental alertness as well.
Several types of abnormal nystagmus exist: peripheral spontaneous, central spontaneous, 
congenital, periodic alternating, gaze-evoked (symmetric, asymmetric, rebound, or disso-
ciated), positional (paroxysmal or persistent), head-shaking, and hyperventilation-induced 
nystagmus, in addition to other ocular oscillations. Complete darkness often provokes nys-
tagmus. When tested with eyes open in darkness, normal subjects commonly have low-
velocity postitional nystagmus (range from 20% to 75%) (McAuley et al., 1996, Bisdorff 
et al., 2000). 
Differentiation between peripheral and central types of nystagmus is essential, but is quite 
difﬁ cult thus far. In spontaneous nystagmus of the central type, the appearance is often pure 
vertical, horizontal, or torsional; ﬁ xation usually has little effect; nystagmus may change 
direction. In comparison, the peripheral spontaneous nystagmus has a combined torsional 
or horizontal appearance; ﬁ xation inhibits nystagmus and is unidirectional. Position change 
may alter central positional nystagmus, suggesting that peripheral otolith input can alter the 
central imbalance.
Gaze-evoked nystagmus
Gaze-evoked nystagmus causes difﬁ culties in maintaining stable conjugate eye deviation 
away from the primary position. The eyes drift back toward the center with corrective 
saccades (fast components) constantly resetting the desired gaze position. Gaze-evoked 
nystagmus is always in the direction of the desired gaze. The causes of abnormality can oc-
cur anywhere from the neuromuscular junction to the oculomotor nuclei of the brain stem. 
Common causes are drugs, metabolic disorders, tumors, infarction, atrophy, multiple scle-
rosis, or myasthenia gravis. Symmetric gaze-evoked nystagmus (equal amplitude to the left 
and right) is often caused by drugs (e.g., diazepam, phenytoin), alcohol, myasthenia gravis, 
multiple sclerosis, or cerebellar atrophy. Asymmetric horizontal gaze-evoked nystagmus, 
on the other hand, may indicate a structural lesion in the brain stem or the cerebellum. 
Rebound nystagmus occurs in patients with cerebellar atrophy or a focal cerebellar lesion, 
and is thus thought to be speciﬁ c for cerebellar involvement. Rebound nystagmus either 
disappears or reverses direction when the lateral gaze position is held. When the eyes re-
turn to the primary position, another burst of nystagmus occurs in the direction of the return 
saccade. Dissociated eye movements with gaze-evoked nystagmus are called internuclear 
ophthalmoplegia: The adducting eye lags behind and develops a low-amplitude nystagmus 
while the abducting eye overshoots the target and develops large-amplitude nystagmus. 
Internuclear ophthalmoplegia usually results from lesions of the medial longitudinal fas-
ciculus, MLF, that most commonly result from multiple sclerosis or vascular disease of the 
brain stem. 
Positional nystagmus
If a semicircular canal cupula is altered so that its speciﬁ c gravity no longer equals that of 
the surrounding endolymph, or if debris inappropriately enters a semicircular canal, the 
canal becomes sensitive to changes in the direction of gravity and can produce positional 
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nystagmus. The classiﬁ cations of positional nystagmus are type I (direction changing), 
type II (direction ﬁ xed), and type III (less clearly deﬁ ned type). Most investigators agree 
on two general categories of positional nystagmus: paroxysmal and persistent.
Paroxysmal positional nystagmus results most commonly for benign peripheral reasons 
but can also arise from lesions of the brain stem and the cerebellum. Benign paroxysmal 
positional vertigo of the posterior canal (BPPV) with a speciﬁ c type of nystagmus is in-
duced by a rapid change from erect sitting to the supine head-hanging left or right position 
(Dix-Hallpike test). It is initially high in frequency but rapidly diminishes. There is a 3- to 
10-second latency before onset, and the nystagmus rarely lasts longer than 30 sec. The nys-
tagmus shows combined torsional and vertical components. A burst of nystagmus occurs 
in the reverse direction when the patient moves back to the sitting position. An essential 
feature is the severe vertigo that the patient experiences on return to the initial position. 
With repeated positioning, vertigo and nystagmus rapidly disappear. 
The central type of paroxysmal positional nystagmus does not decrease in amplitude or 
duration with repeated positioning, does not have a clear latency, and usually lasts longer 
than 30 seconds. The direction is unpredictable and may be different in each position. It is 
often vertical with a downward fast phase. 
Persistent positional nystagmus remains as long as the position is held, although it may 
ﬂ uctuate in amplitude and frequency. Patients with compensated vestibular imbalance due 
to either peripheral or central lesions may develop a transient nystagmus after vigorous 
head-shaking. (Baloh, 2001)
3.4. Laboratory examinations of the vestibular system
To examine the vestibular system adequately, one must isolate it from other sensory sys-
tems. This is a difﬁ cult task at bedside. Here we introduce laboratory examinations used in 
Studies I, II, and V.
Electronystagmography
Electronystagmography (ENG) acts as an electric dipole that measures the difference in 
potential between the cornea and retina (corneal-retinal potential). An electrode placed 
in the vicinity of the eye becomes more positive when the eye rotates toward it and less 
positive when it rotates in the opposite direction. Recordings are usually made with a three-
electrode system; two of the electrodes are placed on each side of the eye, and the reference 
(ground) electrode is placed somewhere remote from the eye. With ENG, nystagmus and 
visually controlled eye movements (saccades, smooth pursuit, and optokinetic nystagmus) 
can be recorded and quantitatively assessed. Often abnormalities not observed during the 
bedside examination are identiﬁ ed. ENG is relatively inexpensive, easily administered, 
noninvasive, does not require head restraint, and is reasonably accurate. On the other hand, 
ENG does not measure torsional eye movements, vertical eye movements are contami-
nated by eye lid artifacts, and the signal-to-noise ratio is poor.
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Computer algorithms have been developed to quantify saccade velocity and accuracy. 
Saccade accuracy is deﬁ ned as the ratio of the saccade amplitude divided by the target 
displacement amplitude times 100. Overshooting of the target rarely occurs in normal sub-
jects. Slowing of saccadic eye movements, both voluntary and involuntary saccades, can 
occur due to lesions anywhere in the diffuse central pathways involved in generating sac-
cades. The most pronounced slowing results from lesions of the pontine gaze centers, the 
oculomotor neurons, or the extraocular muscles. 
Impaired saccade accuracy is most often seen with cerebellar disorders (Zee et al., 1976). 
These diseases most commonly display impaired saccade accuracy with saccade overshoot 
dysmetria. Of the cerebellar syndromes, saccade dysmetria is most prominent with Fried-
reich’s ataxia (Furman et al., 1983). Diffuse degeneration of supranuclear pathways and 
centers in Parkinson’s disease, Huntington’s disease, and in progressive supranuclear palsy 
cause slowing of saccades and hypometria of voluntary saccades. 
Video-oculography
Infrared video recording of eye movements (video-oculocraphy, VOG) is a newer, more 
ﬂ exible eye-movement recording system that is gradually replacing ENG. VOG uses an in-
frared video camera with images stored by a computer for subsequent data analysis. Digital 
signal-processing algorithms are used to determine horizontal, vertical, and even torsional 
eye position. It provides a paper- as well as video recording. Disadvantages include inability 
to wear eyeglasses during the test and difﬁ culty with the digital tracking system in some 
patients with poor contrast between the pupil and iris. VOG is ideal for identifying the pos-
terior canal variant of benign paroxysmal positional nystagmus that produces mostly verti-
cal and torsional nystagmus. Eye blinks can interfere with both ENG and VOG recording 
systems (Baloh, 2001), and the current capture rate is insufﬁ cient for analysis of saccades.
Caloric testing
The caloric test uses a nonphysiologic stimulus (water or air) to induce endolymphatic 
ﬂ ow in the horizontal semicircular canals by creating a temperature gradient in the canal 
system. Irrigation of the external auditory canal with water or air that is below or above 
body temperature transfers a temperature gradient from the external auditory canal to the 
inner ear by conduction. The horizontal semicircular canal develops the largest tempera-
ture gradient because it lies closest to the source of temperature change. For performance 
of caloric testing of the horizontal canal, the patient lies in a supine position with head tilted 
30° upwards. With warm caloric stimulus, the endolymph nearest the middle ear rises due 
to decreased density. This causes the cupula to deviate toward the utricle and produces 
horizontal nystagmus with the fast component directed toward the stimulated ear. A cold 
stimulus produces the opposite effect. The caloric test is the most widely used clinical test 
of the vestibulo-ocular reﬂ ex, because it is easy to apply, and each labyrinth can be stimu-
lated individually. Normal subjects show large variability in caloric responses with many 
methodologic variables in different laboratories. For these reasons, each laboratory should 
establish its own normal range. Usually vestibular paresis is deﬁ ned when there is >25% 
asymmetry between left- and right-sided responses and a directional preponderance with 
>30% asymmetry.
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Posturography
The role of the vestibulospinal system is difﬁ cult to assess when isolated from other sen-
sory systems. A force platform, the simplest method to record postural sway, records the 
position of a subject’s center of mass, in fact the center of pressure, in a standing position 
with the body moving slowly. Some major limitations are evident in static posturography: 
1) the nervous system uses a combination of sensory modalities while standing, and 2) stat-
ic force platforms do not provide controlled stimulus-response measures of vestibulospinal 
function and thus must rely on spontaneous movements of the body. The measurement of 
postural sway might prove useful as a screening test for imbalance, but the information it 
gives is nonspeciﬁ c and cannot identify vestibular lesions (Baloh et al., 1998). 
Dynamic posturography has been designed to overcome these limitations by coupling the 
platform to the sway of the subject. However, moving-platform studies cannot provide 
information on the individual suborgans of the vestibular labyrinth, because in the test situ-
ation many of these suborgans are simultaneously stimulated. Dynamic posturography is 
not a diagnostic test, but rather a method to quantify balance dysfunction under differing 
sensory conditions. (Baloh et al., 1998, Baloh, 2001)
3.5. Neurotologic ﬁ ndings in migraine
Patients with common types of migraine often present with abnormalities in vestibular 
tests; recent studies report abnormalities in up to 34 to 80% of migraine patients (Toglia 
et al., 1981, Kayan and Hood, 1984, Cutrer and Baloh, 1992, Cass et al., 1997). Results 
concerning peripheral labyrinthine dysfunction show variety: abnormalities range from 21 
to 80% in migraine patients, with or without vertigo (Toglia et al., 1981, Cutrer and Baloh, 
1992, Savundra et al., 1997).
ENG abnormalities in migraine show variable results. Most ENG studies in migraine popu-
lations have been carried out in those with ongoing neurotologic symptoms. These studies 
show a range of ENG abnormalities from 34 to 77.5% of migraine patients (Kayan and 
Hood, 1984, Cutrer and Baloh, 1992). Migraine patients with vertigo have presented with 
both central and peripheral vestibular ﬁ ndings (Savundra et al., 1997). 
Posturography studies, as well, have shown conﬂ icting results in migraine patients. Dy-
namic posturography showed abnormalities in 86% of migraine patients with severe, per-
sistent vertigo (Whitney et al., 2000). In contrast, only 19% of patients with migraine-re-
lated vestibulopathy showed abnormalities in dynamic posturography (Cass et al., 1997). 
Migraine-related vestibulopathy included chronic movement-associated disequilibrium, 
unsteadiness, space and motion discomfort, and occasionally, episodic vertigo as an aura.
In migraine patients, it is not common to ﬁ nd hearing loss. In a study with 100 migraine-
related vestibulopathy patients and another study with 91 patients with migraine-related 
dizziness, hearing loss was a rare ﬁ nding (Cass et al., 1997, Cutrer and Baloh, 1992). On 
the other hand, an older study showed that 18% of migraine patients as presenting with 
sensorineural hearing loss (Kayan and Hood, 1984). 
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3.6. Varying oculomotor dysfunction in FHM
FHM1 patients have shown a wide variety of ocular motor disturbances, such as down-
beating nystagmus (Elliott et al., 1996), horizontal gaze-evoked nystagmus (Joutel et al., 
1993, Elliott et al., 1996), and non-speciﬁ c nystagmus (Joutel et al., 1994, Ducros et al., 
1999), as well as no nystagmus (Joutel et al., 1993, Ducros et al., 1999). Only the study 
of Elliot et al. used quantitative eye-movement measurements (ENG). In other studies, a 
neurologist had clinically evaluated possible pathological nystagmus.
To our knowledge, no previous studies cover neurotology of FHM2. Neurological exami-
nations of FHM2 patients have been unremarkable, except in one family, where patients 
showed cerebellar signs (Spadaro et al., 2004).
3.7. Deﬁ nite and subclinical neurotologic ﬁ ndings in EA2
In EA2, interictal nystagmus is a common ﬁ nding together with other signs of cerebel-
lar dysfunction. Oculomotor studies show interictal gaze-evoked, rebound, and downbeat 
nystagmus (Baloh et al., 1986, Baloh et al., 1997, Jen et al., 2004) with features similar to 
those of SCA6 patients (Ying et al., 2001). The ﬁ ndings localize in the oculomotor region 
of the posterior vermis and the fastigial nuclei, namely in the vestibulocerebellum (Oht-
suka and Noda, 1995, Ying et al., 2001). In a recent study, subclinical vestibulocerebellar 
dysfunction was reported in an EA2 family (Subramony et al., 2003). Regardless of age or 
interictal clinical status, all affected subjects demonstrated abnormal saccades, ocular ﬁ xa-
tion, and postural stability. Interestingly, in ocular motor studies, three patients with normal 
neurological status showed several oculomotor abnormalities such as square-wave jerks 
with lateral gaze, hypometric saccades, and both horizontal and vertical components dur-
ing diagonal saccades. Saccadic peak velocity was reduced signiﬁ cantly in these patients, 
which led the authors to suggest that changes in saccade peak velocity might be the earliest 
manifestation of abnormal oculomotor function in EA2 (Subramony et al., 2003).
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4. Proton (1H) Magnetic Resonance Spectroscopy (MRS) 
in migraine and EA2
Magnetic resonance spectroscopy (MRS) is an emerging method to study brain metabo-
lism noninvasively. Proton MRS is available in many clinical MR imagers. 
In MR imaging (MRI), tissue water protons (hydrogen nuclei) are detected, while in MRS, 
protons of molecules other than water are of interest. Thus, MRS allows detection and 
measurement of cellular metabolites of various tissues and organs. In MRS, the proton 
concentration of the metabolites of interest is about 10 000 lower than that of water, so 
the sensitivity of MRS is much lower than that of MRI. This shows as low signal to noise 
ratio, low spatial resolution, and long data-acquisition time in metabolic imaging (MRS) 
compared to traditional water-based imaging (MRI). The MRS experiment is further com-
plicated by the need to saturate the abundant (>80 mol/l) protons of tissue water in order to 
acquire the small signal from the protons of metabolites that appear in mmol/l concentra-
tions. However, the large but relatively constant tissue water signal can serve as a reference 
to quantitate the metabolite signals (Ross and Bluml, 2001, deGraaf, 1998). 
Important concepts in MR experiments are chemical shift and relaxation times T1 and T2. 
T1 and T2 characterize the rate of realignment of protons parallel to the external magnetic 
ﬁ eld after the radio-frequency pulse. This behavior is strongly affected by the differing 
chemical and physical environments of the individual protons. Protons of different mol-
ecules resonate at different frequencies due to their different environments, and thus ap-
pear at different positions on the x-axis of the MR spectrum (chemical shift axis)(deGraaf, 
1998). 
The main metabolites visible in the proton spectrum of the brain are N-acetylaspartate 
(NAA), choline-containing compounds (Cho), creatine-phosphocreatine (Cr), lipids, and 
lactate (Lac). The NAA system appears to reﬂ ect a high degree of cellular intergration 
(Baslow et al., 2003) as well as to be a reversible cerebral osmolyte (Bluml et al., 1997). 
Loss of NAA may indicate loss of number or viability of neurons. NAA appears at low 
levels in tumors, in many white-matter diseases (MS plaques, hypoxic encephalopathy), 
and in atrophic tissue (Bjartmar et al., 2000, Ross and Bluml, 2001). Choline compounds 
(Cho) take part in the lipid metabolism and are present, for example, in cell membrane and 
in the synaptic ends of cholinergic neurons. Cho often shows high levels in many disorders 
because of anabolic or catabolic membrane metabolism. Total creatine (Cr + pCr) repre-
sents the sum of creatine and phosphocreatine. Cr probably plays a role in maintaining 
energy-dependent systems in neurons by serving as a reserve for high-energy phosphates 
and as a buffer of cellular ATP/ADP (Miller, 1991). Brain trauma or hyperosmolar states 
may elevate Cr, while hypoxia, stroke, and tumors may reduce it (Ross and Bluml, 2001). 
Lactate (Lac) is a ﬁ nal product of the anaerobic glycolysis cycle, often increased in isch-
emic brain tissue and in tumors because of hypoxia.
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The brain metabolites show regional differences in the white and gray matter areas. NAA 
is distributed quite homogeneously throughout the brain. Cho show marked regional vari-
ability with the highest concentration in the cerebellum and lowest in the gray matter, with 
a strong caudally decreasing gradient. Cr shows higher concentrations in the gray than in 
the white matter, with its highest levels in the cerebellum. This reﬂ ects the distribution of 
creatine kinase and of energy-requiring processes in the brain. Evidence on the metabolic 
gender differences is conﬂ icting, and so age- and sex-matched control groups in MRS 
studies are preferable (Tedeschi et al., 1995, Pouwels and Frahm, 1998, Riehemann et 
al., 1999). Brain aging is characterized by a reduction in NAA, whereas both Cho and Cr 
increase (Angelie et al., 2001). This suggests reduction in neuronal viability with an ac-
celerated membrane degradation or an increase in glial cell number or both.
4.1. Severe migraine syndromes show decreased brain metabolites 
In common types of migraine, 1H MRS and 31P MRS studies show conﬂ icting evidence for 
brain occipital Lac during and shortly after a migraine attack (Watanabe et al., 1996, Welch 
et al., 1988). Interictal occipital phosphocreatine (PCr) and cortical magnesium show de-
creased levels in MA, with the lowest metabolite levels correlating with severity of mi-
graine syndromes, as in hemiplegic migraine (Lodi et al., 2001, Boska et al., 2002, Uncini 
et al., 1995). Additionally, MA patients with hemisensory, visual, and with motor or speech 
impairment or both displayed reduced cerebellar Cho (Macri et al., 2003).
4.2. High cerebellar lactate peaks in EA2 patients 
Studies using 1H MRS on EA2 are scarce. Bain et al. (1992) and Sappey-Marinier et al. 
(1999) show an increase in cerebellar lactate, but no decrease in metabolites or changes in 
ratios. Acetazolamide treatment, on the other hand, causes a pH decrease as well as a de-
crease in PCr/Pi, and ATP/Pi ratios (Sappey-Marinier et al., 1999). These ﬁ ndings possibly 
explain the beneﬁ cial effects of acetazolamide in EA2.
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AIMS 
This study was undertaken to better elucidate pathophysiological mechanisms underlying 
common types of migraine, familial hemiplegic migraine (FHM), and episodic ataxia type 
2 (EA2). The aims were to study neurotological ﬁ ndings in migraine and EA2, and to study 
cerebellar metabolism and genetics in one EA2 family.
More speciﬁ cally, the aims of this study were to characterize:
• neurotologic ﬁ ndings by means of quantitative measures of vestibular and auditory 
function in migraine patients with and without aura (I).
• neurotologic ﬁ ndings in familial hemiplegic migraine (II). 
• possible vestibulocerebellar involvement and the effect of acetazolamide on these 
abnormalities in EA2, and by genetic methods to identify a mutation in one EA2 
family (III, V).
• cerebellar metabolic abnormalities in EA2 by proton magnetic resonance spectros-
copy (IV).
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PATIENTS AND METHODS
5. Patients and controls
5.1. Migraine with and without aura
For the neurotologic study (I), we examined 36 migraine patients: 12 with MA and 24 with 
MO. Each patient group had a strong family history of its type of migraine. MA patients 
were recruited from six unrelated families, while MO patients were identiﬁ ed from the 
Finnish Twin Cohort Study (Kaprio et al., 1978), in 14 unrelated families. MA patients had 
several types of migraine with aura: basilar migraine (two patients), FHM (two), hemiple-
gic migraine (three), and migraine with typical visual aura (ﬁ ve) (Table 2). Five patients 
were on beta-blocker medication and eight on anticoagulants, acetosalicylate, or statins. 
Controls (I) were 41 healthy nonmigrainous volunteers (Table 3), collected from among 
the personnel of the Department of Otolaryngology of the Helsinki University Central 
Hospital. Control groups were test-speciﬁ c. Static posturography and ENG controls were 
studied in 1998 and 1995 by the same technique and with the same equipment as in the 
present studies (I, II, V), and these results have been of clinical use ever since (Isotalo, 
1999, Juhola et al., 1989, Starck et al., 1992). 
Table 2. Demographic features of patients from Studies I-V, including the extended EA2 family.
Number of patients Female Male Mean age SD
MA 12 11 1 44 17
MO 24 19 5 47 8
FHM2 9 7 2 30 14
EA2 18 11 7 37 14
MA = migraine with aura, MO = migraine without aura, FHM2 = familial hemiplegic mi-
graine with aura type 2, EA2 = episodic ataxia type 2, SD = standard deviation
Table 3. Demographic features of controls in Studies I-II, IV-V. 
Number of controls Female Male Mean age SD
VOG 12 6 6 40 11
ENG 16 9 7 40 9
Static posturography 13 8 5 46 8
1H MRS 9 6 3 36 8
VOG = video-oculography, ENG = electronystagmography, 1H MRS = proton magnetic resonance spectroscopy
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5.2. Familial hemiplegic migraine type 2
From one large FHM2 family, 15 subjects underwent examination (Figure 6 A). Nine 
FHM2 patients underwent neurotologic tests (Study II; Table 2). All were carriers of a 
T345A mutation of the ATP1A2 gene (Kaunisto et al., 2004). The patients were on no 
permanent medication.
5.3. Episodic ataxia type 2
Neurologic examination was performed on 18 patients (9 women) from a large, extended 
EA2 family (Figure 6 B). Each of these patients, of whom one was asymptomatic, had a 
novel CACNA1A splice site mutation (Study III; Table 2). Neurotologic tests were carried 
out on 12 patients (6 were women, mean age 36; SD 16 years), 3 of them were examined 
with and without acetazolamide treatment (V). 1H MRS studies (IV) were carried out on 9 
patients (6 women, 3 men), mean age 35, SD 9 years, 7 of these were on acetazolamide 500 
mg/day, but those studied had a week of wash-out time before examination.
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Figure 6. Pedigrees with familial hemiplegic migraine type 2 (A) and with episodic ataxia type 2 (B). Mutation 
status as + or -. Black symbols denote those clinically affected. Those containing a dark dot denote an asymptom-
atic mutation carrier. In family A, half-darkened symbols denote patients with migraine without aura. In family B, 
the quarter-darkened symbol denotes an individual with a speciﬁ c sensitivity to alcohol.
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Controls for the 1H MRS study (IV; Table 3) were 9 healthy volunteers. Two of the controls 
had migraine with aura, with their last attacks 6 and 11 years previously. Controls used no 
medication.
All these study protocols were approved by the Ethics Committee of the Helsinki Univer-
sity Central Hospital, and all subjects gave their informed consent.
6. Genetic methods
Linkage analysis
Linkage to the 19p13 CACNA1A locus was tested by use of microsatellite markers 
D19S221, D19S1150, and D19S226. Genotyping was performed with the ALFexpress se-
quencer (Amersham Biosciences, Uppsala, Sweden) (Virolainen et al., 2000). Asymptom-
atic EA2 family members under age 20 and an individual (IV:9) with an unusual sensitivity 
to alcohol as her only symptom were considered as being of unknown status. Equal allele 
frequencies were used. 
Two-point LOD scores were calculated with the MLINK option of the LINKAGE program 
package under the assumption of an autosomal dominant inheritance with incomplete pen-
etrance of 0.8 and disease gene frequency of 0.0001 (Lathrop and Lalouel, 1984). 
Mutation analysis
The proband (IV:13) and his mother (III:18) were analyzed for mutations in CACNA1A. 
Two healthy subjects served as controls. All exons and immediate ﬂ anking intronic se-
quences were ampliﬁ ed by polymerase chain reaction (PCR) and analyzed by cycle se-
quencing using the BigDye Terminator Ready Reaction Kit (Applied Biosystems, Foster 
City, CA, USA) on the ABI Prism 377 automatic sequencer (Applied Biosystems). All 
PCR products were sequenced in both forward and reverse directions. Nucleotide number-
ing of CACNA1A is according to GenBank sequence X99897.
Within the EA2 family, cycle minisequencing was used to demonstrate the segregation 
of the speciﬁ c mutation and to exclude the presence of the mutation in 132 healthy, unre-
lated controls (Jarvelainen et al., 2001). Exon 37 was ampliﬁ ed by PCR using primers 5´-
CCAGTCTCTCCCACTCCTTC-3´ and 5`-TGAAGAACCCCAAGCCACA-3`. We used 
biotinylated reverse primer 5`biotin-CCTTATAATGAATCCGACCGC-3`and 3H-labeled 
nucleotides dTTP (wild type) and dCTP (mutated sequence) for the cyclic primer exten-
sion.
Controls
A total of 132 healthy, unrelated, voluntary blood donors of Finnish origin served as con-
trols. None was found to have the mutation in question.
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7. Neurotologic methods
7.1. Video-oculography
Eye movements were measured during discrete periods of 30 seconds in different eye, 
head, and body positions. The interval between different test conditions was approximately 
1 min. A rubber mask-mounted small video camera (Sensomotoric Instruments, Berlin, 
Germany) recorded movements of the dominant eye that was in total darkness while the 
other eye was covered. Patients were instructed not to blink and to keep their eyes open 
during measurements. There was no ﬁ xation target illuminated. Test conditions were 1) 
body prone, head straight ahead, and gaze forward; 2-3) gaze approximately 30° to the left 
or right; and 4) after passive head shaking to the right and left 30 times in the yaw plane. 
After this, positional nystagmus was evaluated by Dix-Hallpike positioning: 1) supine, 
facing straight ahead, and 2-3) supine, head rotated 45° to the left or right and the neck 
overextended. Finally, with the subject remaining supine, lateral head turns for 15 seconds 
were applied six times to study BPPV of the horizontal canal. VOG recordings were stored 
as eye-position curves in the horizontal and vertical plane, and also on standard VHS vid-
eotape. Analysis was done off-line.
The VOG analysis included simultaneous evaluation of eye position curves and videotapes 
for spontaneous nystagmus, gaze-evoked nystagmus, head-shaking nystagmus, and posi-
tional nystagmus. An abnormal nystagmus was deﬁ ned by calculating maximal slow phase 
velocity and direction, and was compared to normal values (mean ± 2 SD) derived from 
healthy controls.
7.2. Electronystagmography and caloric testing
Saccade velocity, accuracy, and latency were determined for pseudorandom saccades of 
20° and 60° to the left and right (Juhola et al., 1989). Saccades were classiﬁ ed as abnormal 
when the mean accuracy of either 20° or 60° saccades was abnormal with regard to the nor-
mal limits (mean ± 2 SD). Caloric testing was evaluated for side difference (a 30% differ-
ence considered signiﬁ cant) and bilateral hypofunction (maximal slow phase velocities of 
nystagmus for cold (30°) and warm (44°) caloric stimulus not exeeding 12° per second).
7.3. Static posturography and audiometry
Four test conditions were used in posturography: sway velocities (mm/second) with 1) 
eyes open and 2) closed, as well as 3-4) with or without bilateral calf-muscle stimula-
tion (vibration perturbation of 30 Hz with calf-attached vibrators weighing 400 grams). 
Each test condition was recorded for 30 seconds: ﬁ rst with eyes open, then eyes open with 
12-second calf-muscle stimulation; after that the same procedure with eyes closed. The 
interval between the second and third paradigm was 15 seconds (Starck et al., 1992). Au-
diometry was carried out by the standard procedure in clinical use.
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8. Proton (1H) Magnetic Resonance Spectroscopy (MRS)
We used a 1.5 T whole-body MR system (Siemens Magnetom Sonata, Erlagen, Germany) 
equipped with a standard head coil. Oblique axial, coronal, and sagittal T1-weighed gradi-
ent echo images (FLASH sequence with repetition time (TR) 225 ms, echo time (TE) 4.8 
ms, and a 70° ﬂ ip angle) were used to position the spectroscopic voxels in cerebellar hemi-
spheres, vermis, and left thalamus (Figure 7). Single-voxel 1H MRS measurements were 
performed using the point-resolved spectroscopy sequence, PRESS, with the chemical shift 
selective water suppression scheme, and with TE 288 ms and TR 1600 ms. Voxel volumes 
ranged from 3.38 to 8.00 cm3. Spectral width was 1000 Hz, number of aquired complex data 
points was 1024, and 256 acquisitions were recorded. The spectra were processed and ana-
lyzed by a MR-spectroscopy package of Mrease-software (Siemens, Erlangen, Germany). 
The time domain sig-
nals were apodized 
by use of the Hanning 
function with a 400 ms 
width at half-maximum 
and zero ﬁ lled once pri-
or to Fourier transfor-
mation. N-acetylaspar-
tate (NAA, 2.02 ppm), 
total creatine (3.03 
ppm, including signals 
from creatine, Cr, and 
phosphocreatine, PCr), 
and choline-containing 
compounds (Cho, 3.22 
ppm) signal intensities 
were measured with 
Gaussian lineshape ﬁ t-
ting. Intensities were 
corrected for differenc-
es in coil loading and 
voxel size.
Figure 7. Voxel positions 
in the left thalamus (A), the 
vermis (B), and cerebellar 
hemispheres (C) with patient 
spectra.
Cho, choline compounds; 
Cr, creatine: Lac, lactate;
NAA, N-acetylaspartate.
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9. Statistical methods
Results for neurotologic tests (means ± 95% CI) between the groups were compared by 
Kruskal-Wallis κ2 test or Mann-Whitney U-test for noncontinuous parameters (SPSS, ver-
sion 8.0, SPSS Inc., Chicago, IL).
The 1H MRS metabolite signal intensities (in arbitrary units) were analyzed by two-tailed 
t-test assuming unequal variances.The level of signiﬁ cance was set at p<0.05.
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RESULTS 
10. Clinical ﬁ ndings
10.1. Patients with common types of migraine 
Of the 36 migraine patients, 12 had MA and 24 MO. Of the 12 MA patients, seven had a 
severe type of aura (vertigo, hemisensoric symptoms, or mild hemiparesis), while ﬁ ve had 
only a visual aura. During migraine attacks, two with MO and one with typical MA had 
nonspeciﬁ c dizziness (a giddy sensation), while two patients with BM had severe vertigo 
(an illusion of rotation).
Patients were mostly asymptomatic interictally: Occasional dizziness occurred in two MA 
patients between attacks, and two with MA had a history of positional vertigo.
Neurologic examination was normal in 34 of 36 migraine patients. Two patients, one with 
BM and one with FHM, had nystagmus in lateral gaze.
10.2. Variation in clinical features of attacks in FHM2
From a large FHM2 family (Figure 6 A), 11 patients fulﬁ lled criteria for FHM according 
to the IHS criteria (International Headache, 1988, Headache Classiﬁ cation Subcommit-
tee of the International Headache, 2004). Neurologic examination in all FHM patients 
was normal. The clinical picture of migraine attacks showed heterogeneity: Most patients 
had migraine attacks that often started with a gradually spreading hemisensoric aura and 
thereafter were accompanied by dysarthria, dysphasia, mild to moderate hemiparesis, and, 
in some individuals, confusion or decreased consciousness. For most of these patients, the 
hemiplegic aura could last for days or even weeks. In four patients, severe vomiting could 
last for days. Two patients did not report migraine attacks, but when hospitalized due to 
mild head trauma that had induced confusion and decreased consciousness, a barely detect-
able hemiparesis was recorded in the medical history. Mild head trauma triggered migraine 
attacks in ﬁ ve patients, but three of these had migraine attacks even without speciﬁ c trig-
gers.
The patients from this FHM2 family considered migraine attacks as placing constraints on 
their lives and causing social withdrawal. Acetazolamide (250 mg twice a day) and also 
verapamil (80 mg twice a day) exhibited good efﬁ cacy in preventing migraine attacks in 
two of the patients, thus helping them to lead normal lives.
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10.3. Typical phenotype in EA2
EA2 attacks were primarily of similar type among family members, Figure 6 B. Two of the 
subjects were asymptomatic (III:23 and IV:9) with a particular sensitivity to alcohol. Dur-
ing attacks the most common symptoms were vertigo, ataxia, dysarthria, nausea, vomiting, 
blurred vision, and fatigue. Some patients presented with double vision or generalized 
weakness, one patient presented with migrainous headache during ataxia episodes that ful-
ﬁ lled basilar migraine criteria (Headache Classiﬁ cation Subcommittee of the International 
Headache, 2004). Attacks commonly started in childhood (mean age 12, range 4-35) and 
lasted typically about 2 hours, but in one patient (IV:24) could last for days. Triggering 
factors were often emotional stress, physical exercise, heat, alcohol, sometimes coffee or 
fasting. Rest, often a short nap, relieved symptoms in all patients. 
Seven patients were on acetazolamide to prevent EA2 attacks. Most of these patients re-
sponded extremely well to acetazolamide (250 mg twice a day) with a dramatically reduced 
attack frequency. Two individuals (IV:13 and IV:16) had attacks about once a month de-
spite medication, but the severity, duration, and frequency decreased overall. We increased 
the acetazolamide dose to 1000 mg per day to better reduce attacks in these individuals, 
but due to side-effects (urethrolithiasis and metabolic acidosis) the dose had to be reduced 
to 500 mg per day.
For most patients, neurological interictal examination was either normal (5/18) or with 
only minor clinical ﬁ ndings (8/18). These included mild limb ataxia on knee-heel testing, 
difﬁ culties in tandem gait, or nystagmus at lateral gaze. However, four individuals had 
cerebellar ataxia ranging from mild (3/18) to severe (1/18), accompanied by dysarthria 
and pronounced gaze-evoked nystagmus. These ﬁ ndings were consistent with cerebellar 
atrophy in MRI.
Migraine headaches appeared in three patients together with ataxic spells, but six patients 
had MO attacks independent of EA2 attacks. 
11. Genetics of EA2
Linkage analysis
The maximum two-point LOD scores of 4.48 (θ=0), 3.81 (θ=0), and 3.49 (θ=0) revealed 
linkage to 19p13 in our EA2 family with 13 clinically affected subjects with the markers 
D19S226, D19S1150, and D19S221. 
Mutation analysis
Sequencing of CACNA1A showed, in the proband and his mother, a heterozygous single 
nucleotide change from A to G (IVS36-2A>G substitution) at the 3’ acceptor splice site of 
intron 36. A minisequencing method was used to detect the mutation in the rest of the fam-
ily. A total of 17 family members carried the mutation, 13 of them clinically affected (II). 
In further study, the family was extended (V), and the mutation was conﬁ rmed from four 
40
additional clinically affected family members (III:21, III:22, III:25, IV:32) in addition to 
one asymptomatic subject with a particular sensitivity to alcohol (III:23).
12. Neurotologic tests
We examined the 36 patients with common types of migraine, the family with episodic 
ataxia type 2 (N=12), and the family with familial hemiplegic migraine type 2 (N=9) by 
a neurotologic test pattern (see Table 4). The results were compared to those of healthy 
controls. 
Table 4. Number of abnormal neurotologic ﬁ ndings in each patient group.
 
Number of 
patients
VOG ENG
Caloric 
responses
Static 
posturography
Audiometry
MA 12 6 4 0 7 3
MO 24 8 7 4 10 2
FHM2 9 4/7 tested 2 1 3 0
EA2 12 8 7 0 7/10 tested 0
VOG = video-oculography, ENG = electronystagmography, MA = migraine with aura, MO = migraine without 
aura, FHM2 = familial hemiplegic migraine type 2, EA2 = episodic ataxia type 2. 
12.1. Subclinical vestibulocerebellar dysfunction in the common types of 
migraine
In neurotologic tests, 30 of 36 patients (83%) had abnormalities (Table 4). Of the 36 pa-
tients, 16 (44%) had abnormalities in one, while 14 patients (39%) had abnormalities in 
more than one test. Only 17% had all test-results within normal limits: four patients with 
MO and two with MA (one with typical MA and one with FHM). 
Video-oculography
Abnormal nystagmus occurred in 14 of 36 (39%) of the migraine patients (p=0.02). Nys-
tagmus, suggestive for central type, was evident in 10 of 14 subjects, 2 of 14 had BPPV, 
and 2 had nystagmus with possible peripheral or central etiology. Pathologic ﬁ ndings tend-
ed to be more severe in MA (p=0.003) than in MO (p=0.03), although this difference was 
nonsigniﬁ cant (p=0.23). 
Central pathologic nystagmus was deﬁ ned as follows: 1) direction-changing gaze nys-
tagmus, which was asymmetric, occurred in a vertical plane despite horizontal gaze, or 
occurred together with head-shaking nystagmus or spontaneous nystagmus; 2) positional 
nystamus, which was two-dimensional (occurring simultaneously in both vertical and hori-
zontal planes). Peripheral nystagmus showed, during positioning, typical features of tor-
sional and vertical nystagmus of BPPV of the posterior semicircular canal.
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ENG and caloric testing
Saccadic inaccuracy showed a signiﬁ cant difference in 4 of 12 of the MA (33%) and 7 of 24 
of the MO patients (29%) when compared to controls (p=0.001). MA and MO did not differ 
signiﬁ cantly (Study I, Figure 1, p.1750). Saccades were hypermetric in six patients and hy-
pometric in ﬁ ve. Saccadic latencies and peak velocities were within normal limits. Caloric 
responses in 4 of 24 of the MO subjects were asymmetric; one of these also had bouts of 
vertigo during a migraine attack. None of the patients with asymmetric caloric responses 
had any history of vestibular abnormality. There was no bilateral caloric hypofunction.
Static posturography
Static posturography showed increased body sway in 7 of 12 (58%) of the MA patients, and 
in 10 of 24 (42%) of the MO patients, this difference being signiﬁ cant (p=0.001) compared 
to those of the controls when the test was performed with eyes open (Study I, Figure 2, 
p.1750). MA patients tended to have higher body sway velocities than did MO patients. 
Audiometry
Hearing level was abnormal for 5 of 36 (14%). One migraineur had a slight conductive 
unilateral hearing loss, and the other showed a slight unilateral sensorineural hearing loss. 
Three had symmetric bilateral sensorineural hearing loss: one apparently due to noise ex-
posure and age (71 years), one most likely due to presbyacusis, and one due to unknown 
etiology.
12.2. Abnormal oculomotor and postural function in FHM2
For neurotologic tests, at least one of the tests was abnormal for 7 of 9 patients. Two pa-
tients (II:6, II:10 in Figure 6A) were normal in all tests. 
Video-oculography
In video-oculography, 4 of 7 patients had abnormal results with the central type of posi-
tional nystagmus and in one patient (III:7) also gaze-evoked nystagmus. VOG results dif-
fered signiﬁ cantly from those of the controls (p=0.02).
Saccades and caloric responses
Two patients (II:4, III:9) had hypometria for 60° saccades. Mean saccadic accuracy was 
decreased for 60° saccades (p=0.02) when compared to controls. Caloric responses were 
normal, except for one patient (III:14) with unilateral weakness.
Static posturography and audiometry
Body sway velocity was increased in 3 of 9 of the patients (III:9, II:11, III:11). In test 
conditions with eyes open, mean body sway velocity was signiﬁ cantly increased when 
compared to that of controls (p=0.03). Audiometry in all patients was normal.
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12.3. Deﬁ nite and subclinical vestibulocerebellar dysfunction in EA2 
Of the 12 EA2 patients examined, 11 had abnormalities in at least one test (in part, un-
published data). Only one patient (IV:24) was normal on all tests. Patients with permanent 
cerebellar atrophy and ataxia had the most severe ﬁ ndings. Abnormal ﬁ ndings seemed to 
correlate neither with age nor with gender. In particular, we examined the effect of acet-
azolamide on abnormal neurotologic ﬁ ndings in three patients (Study III).
Video-oculography
VOG showed abnormal nystagmus in 8 of 12 of these patients (p=0.001). Abnormal nys-
tagmus types were spontaneous (4/12), gaze-evoked or rebound (4/12), and central posi-
tional (8/12) nystagmus. Acetazolamide improved the VOG ﬁ ndings (Study III, Figure 2, 
p. 233) in two patients (IV:16, IV:22). Those with cerebellar ataxia had the most severe 
nystagmus ﬁ ndings (Figure 8).
ENG and caloric responses
Saccadic accuracy both at 60° and 20° saccades was signiﬁ cantly decreased in patients 
compared to that of controls (p<0.001). Saccadic dysmetria was found in 7 of 12 of the 
patients. Three subjects had hypermetric saccades, but four had both hypermetric and hy-
pometric saccades. Saccadic velocities and latencies fell within normal limits. Acetazol-
amide improved hypermetric saccades in one patient (IV:13). None of the patients showed 
caloric weakness.
Static posturography and audiometry
In static posturography, 7 of 10 of the patients showed increased body sway velocity, es-
pecially in eyes-open test conditions, when compared to that of controls (p=0.002). Two 
patients (III:8, III:14) were not tested because of severely impaired balance. Acetazolamide 
improved abnormal posturography in one patient (IV:22).
10 s
Figure 8. A 40-second sample of an 
eye-position signal from an EA2 patient 
during saccade testing. Time scale below. 
Note the hypermetric eye movements after 
most eye-position changes. Broken lines 
indicate ± 30° range of maximal target 
position.
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12.4. Comparison of neurotologic ﬁ ndings in common types of migraine, 
in FHM2, and in EA2 
We compared the neurotologic ﬁ ndings in FHM2, MA, and MO (Study II), and on the other 
hand in EA2 (in part, unpublished data). The accuracy in 20° saccades was signiﬁ cantly 
decreased in MO patients when compared to that of FHM2 patients (p=0.02). Furthermore, 
20° saccadic accuracy in EA2 patients was signiﬁ cantly decreased when compared to that 
of FHM2 patients (p=0.01) (Figure 9). EA2 patients showed signiﬁ cantly more abnormal 
nystagmus in the VOG than MO patients did (p=0.03). No signiﬁ cant differences appeared 
between the groups in static posturography (Figure 10).
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12.5. Neurotologic ﬁ ndings in controls
In video-oculography, nystagmus was quite frequent among control subjects. However, the 
mean slow-phase velocity for nystagmus was very low. Controls displayed no pathological 
nystagmus, such as gaze-evoked nystagmus (Levo et al., 2004). In ENG, controls had nei-
ther hypermetric nor hypometric saccades. The mean saccadic accuracy (±CI) for controls 
was 3.7° (±0.9) for 60° saccades and 2.0° (±0.3) for 20° saccades. In static posturography, 
the controls did not show as much body sway as did the patients, but the individual vari-
ance in sway velocity between control subjects was large. 
13. Proton magnetic resonance spectroscopy showing decreased 
cerebellar total creatine in EA2
We examined nine EA2 patients by 1H MRS and measured ratios of Cr/H2O, Cho/H2O, 
NAA/H2O, and Lac/H2O in both cerebellar hemispheres, in the vermis, and in the left 
thalamus (Figure 7). Among the nine EA2 patients, one showed marked vermian atrophy 
in brain MRI.
In the cerebellar hemispheres, tCr/H2O signal intensities were 12% lower in patients than 
in controls (p=0.005), but no difference appeared in NAA. Neither cerebellar Cho/H2O nor 
Lac/H2O showed a statistical difference when compared to controls (Figure 11).
In the vermis, tCr/H2O was 16% lower in patients than in controls (p=0.007). NAA, Cho, 
and Lac ratios showed no signiﬁ cant difference from those of controls.
In the left thalamus, no signiﬁ cant differences appeared in NAA/H2O, tCr/H2O, Cho/H2O, 
or Lac/H2O between patients and controls.
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DISCUSSION
By neurotologic testing (VOG, ENG, caloric responses, static posturography, and audiom-
etry), we studied vestibulocerebellar changes in 36 patients with migraine with or without 
aura, 9 patients with FHM2, and 12 patients with EA2. Three patients with EA2 were exam-
ined with and without acetazolamide treatment. Healthy, nonmigrainous controls were test-
speciﬁ c: 12 controls for VOG, 16 for ENG, and 13 for static posturography. These studies 
suggest subclinical oculomotor and postural changes in the common types of migraine as well 
as in FHM2 and EA2. Proton MRS was carried out for nine EA2 patients and nine healthy 
controls with special reference to the cerebellum. Cerebellar total creatine was lower than in 
the controls, which may have been an early sign of calcium channel dysfunction in mostly 
nonataxic EA2 patients. A novel CACNA1A mutation was identiﬁ ed in an EA2 family.
14. Migraine with and without aura, FHM2, and EA2 displaying 
subclinical vestibulocerebellar dysfunction
Neurotologic ﬁ ndings in our study on MA and MO patients (I) suggest subclinical vestibu-
locerebellar dysfunction in both types of common migraine. These patients were mostly as-
ymptomatic in respect to neurotologic symptoms and had a strong family history of either 
MA or MO. We thus put our emphasis on migraine as the study focus. Interestingly, for the 
common types of migraine, a three-dimensional analysis of reaching movements has also 
shown subclinical cerebellar impairment (Sandor et al., 2001).
Most studies on neurotology of the common types of migraine have been retrospective 
(Harker and Rassekh, 1988, Cutrer and Baloh, 1992, Savundra et al., 1997, Whitney et al., 
2000), have included few patients (Harker and Rassekh, 1988), or have emphasized either 
episodic or chronic vertigo (Dieterich and Brandt, 1999, Neuhauser et al., 2001, Cass et al., 
1997). This complicates the comparison of our data with that of previous studies. Never-
theless, our data with an 83% proportion of neurotologic abnormality in migraine patients 
agree with data from several other studies (range, 34%-80%) (Toglia et al., 1981, Kayan 
and Hood, 1984, Cutrer and Baloh, 1992, Cass et al., 1997).
Moreover, neurotologic studies on migraine show somewhat conﬂ icting results. Several 
show a variety in the proportion of migraine patients with ENG abnormalities (range, 34%-
77.5%) (Kayan and Hood, 1984, Cutrer and Baloh, 1992, Dieterich and Brandt, 1999). 
The diversity is even clearer in the proportion of migraine patients having labyrinthine 
dysfunction (range, 8%-80%) (Toglia et al., 1981, Cutrer and Baloh, 1992, Dieterich and 
Brandt, 1999). In our study (I), ENG abnormalities occurred in 29% of MO and 33% of 
MA patients, while only 17% of the MO patients and none of the MA patients showed 
unilateral caloric weakness. Others’ results differ depending on whether patients have on-
going neurotologic symptoms. Moreover, MA patients that present with vertigo commonly 
have shown both central and peripheral vestibular dysfunction (Savundra et al., 1997). We, 
as well, found signs indicative for peripheral vestibular dysfunction: 22% of our patients 
showed BPPV, unilateral caloric hyporeactivity, or the suggestive peripheral type of nys-
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tagmus in the VOG. In short, we detected signs of peripheral and central vestibular nystag-
mus in migraine, but the abnormalities were mostly of vestibulocerebellar origin.
In Study I, MA and MO showed a similar type of neurotologic ﬁ ndings, with features of 
central etiology in VOG. The central type of positional nystagmus ﬁ ndings (in 28% of the 
patients) were composed mostly of horizontal and vertical components with no known 
peripheral pathology or vertigo symptoms during positional testing. Some of these patients 
also had simultaneous gaze-evoked nystagmus, which occurred without positional nystag-
mus in 25% of them. Moreover, our patients showed saccadic inaccuracy with hypo- and 
hypermetric saccades as well as increased body sway in static posturography, which sup-
port — together with the VOG ﬁ ndings — our conclusion of subclinical vestibulocerebel-
lar dysfunction in migraine patients.
FHM2 is such a new entity that, to our knowledge, no previous neurotological studies on 
FHM2 have appeared. In Study II, neurological examination in all FHM2 patients was 
normal, but neurotologic tests showed subclinical changes consistent with those seen in 
more common types of migraine. FHM2 patients showed heterogeneity in oculomotor and 
postural dysfunction: Most of the patients examined had the abnormal central type of posi-
tional nystagmus in VOG, while some had abnormalities only in postural control. This may 
suggest phenotype variation within speciﬁ c ATP1A2 mutation carriers.
Cerebellar signs are present in about 20% of FHM1 families, while the phenotype of 
FHM2 has not displayed cerebellar signs (Ducros et al., 1997, 2001,Gardner et al., 1997, 
Marconi et al., 2003), except for one Italian family (Spadaro et al., 2004). The normal 
neurological examinations in our patients support the theory that the major FHM2 pheno-
type is pure, i.e., without cerebellar signs. We had heterogeneous, subclinical oculomotor 
and postural ﬁ ndings that were not speciﬁ cally localizing. On the other hand, one patient 
showed gaze-evoked nystagmus which was suggestive of vestibulocerebellar origin. The 
cerebellar involvement in FHM2 is as yet unclear, but defective ion channel mechanisms 
in the cerebellum offer interesting insights into their disease pathophysiology. The Na+,K+ 
-ATPase pump in astrocytes is impaired in FHM2 due to ATP1A2 gene mutation. This 
causes impaired maintenance of an electrochemical Na+ and K+ gradient, which may affect 
neurons and astrocytes in various ways: It may depolarize neurons, facilitate CSD, impair 
astrocytes in their glutamate removal, and activate the Na+,Ca2+ exchanger (Juhaszova and 
Blaustein, 1997, Van Den Maagdenberg et al., 2004, Moskowitz et al., 2004). The latter 
may eventually cause an increase in intracellular Ca2+ and thus lead to similar type of 
changes in neurons in FHM2 as in FHM1 (De Fusco et al., 2003).
A genetic basis and chronic cerebellar ataxia in part unite FHM1 and EA2, with con-
siderable overlap also in their clinical phenotype. Despite these overlapping phenotypes, 
an increasing number of identiﬁ ed mutations in the CACNA1A have become feasible for 
diagnosing both FHM1 and EA2 patients. The causative mechanisms associated with the 
development of ataxia are as yet unknown. In one FHM1 family, abnormal eye movements 
that suggest vestibulocerebellar dysfunction have been documented, possibly indicating 
early manifestations of cerebellar atrophy (Elliott et al., 1996). 
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Abnormal interictal oculomotor function has been documented in EA2 with typical features 
of gaze-evoked, rebound, or downbeat nystagmus (Baloh et al., 1997, Jen et al., 2004). In 
a recent study of EA2 patients, half the patients had normal interictal status, similar fea-
tures in oculomotor dysfunction, and abnormal dynamic posturography (Subramony et 
al., 2003). Our ﬁ ndings with abnormal neurotologic test results in 11 of 12 patients from 
an EA2 family agree with those results. Vestibulocerebellar dysfunction did not seem to 
depend on neurological status. These ﬁ ndings may indicate functional changes in the cer-
ebellum before the atrophy and death of Purkinje cells (Subramony et al., 2003).
Acetazolamide prevents, most often extremely well, ataxic episodes, but has not previously 
improved baseline interictal ocular motor signs (Baloh and Winder, 1991). In Study III, 
however, three patients from our EA2 family showed improvement in baseline neuroto-
logic tests while on acetazolamide. It possibly stabilizes dysfunctioning Cav2.1 channels 
in Purkinje cells where the most abundant neuronal expression of CACNA1A gene occurs. 
Improvement in baseline oculomotor and postural abnormalities, in contrast to previous 
ﬁ ndings, may also reﬂ ect the diversity of dysfunctioning Cav2.1 channels. With increasing 
data on genotype-phenotype correlations for EA2, it has become evident that one cannot 
predict baseline ataxia, interictal nystagmus, or acetazolamide responsiveness by type of 
mutation (Jen et al., 2004). With documented mutations, clinical features vary between and 
within families (Van Den Maagdenberg et al., 2002, Jen et al., 2004).
Overall, EA2 patients, although mostly with normal interictal neurological status, showed 
the most abnormal results in neurotologic tests when compared to MA, MO, or FHM2 
patients. These four patient groups showed signiﬁ cant abnormalities in neurotologic tests 
when compared to controls’ tests, with suggestive vestibulocerebellar dysfunction as a 
common feature. This may reﬂ ect intrinsic ion channel dysfunction in cerebellar and 
brain stem neurons, with the most evident abnormal ﬁ ndings appearing in EA2 patients. 
FHM2 causing Na+,K+ ATPase pump dysfunction may lead to Ca2+ overload in neurons 
(De Fusco et al., 2003), which may explain the features of subclinical oculomotor dys-
function in the present FHM2 family. However, in neurotologic ﬁ ndings, patients with 
the common types of migraine, with no genetically deﬁ ned background, showed similar 
features. This suggests that the cerebellum and most probably the brain stem both play a 
role in the pathophysiology of various types of migraine. It has been debated whether cal-
cium channel regulating genes occur in the common types of migraine as well, but results 
are conﬂ icting (Terwindt et al., 2001, Noble-Topham et al., 2002). Interestingly, neuro-
physiological and imaging studies on common types of migraine have, on the other hand, 
pointed to subclinical cerebellar dysfunction (Sandor et al., 2001, Kruit et al., 2004) or to 
possible impaired neuromuscular transmission (Ambrosini et al., 2001). These features 
may reﬂ ect CACNA1A dysfunction, but the study populations have not been genetically 
deﬁ ned.
EA2 patients showed the most severe saccadic inaccuracy, with a signicant difference from 
that of FHM2 patients. Interestingly, MO patients showed a signiﬁ cant difference in sac-
cadic inaccuracy from that of FHM2 patients, as well. These comparisons suggest that 
migraineurs in general may exhibit dysmetria in fast voluntary eye movements, whether 
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in common type or hemiplegic migraine, but with more severe ﬁ ndings in patients with an 
actual CACNA1A mutation.
15. Complex phenotype-genotype correlation in EA2 
Remarkable variation exists in the clinical expression of the EA2 phenotype — symptoms 
may range from migraine to progressive ataxia (Denier et al., 1999, Jen et al., 2001, Jen et 
al., 1999, Jouvenceau et al., 2001, Van Den Maagdenberg et al., 2002, Subramony et al., 
2003). Our EA2 family was consistent with this observation: Age of onset and duration of 
attacks, as well as neurological examinations showed variation. Most likely, in addition to 
disease-causing CACNA1A mutation, either modifying genetic or environmental factors, or 
both, play a role in the clinical expression of EA2 (Van Den Maagdenberg et al., 2002).
In Study IV, we suggest that decreased cerebellar total creatine (tCr) may, in addition to de-
creased cerebellar PCr/Pi or ATP/Pi, reﬂ ect neurochemical changes as a consequence of dys-
functioning neuronal calcium channels. The exact mechanism how an impaired Cav2.1 chan-
nel causes the episodic ataxic symptoms and eventual cerebellar atrophy is unknown. Recent 
studies on functional consequences of CACNA1A mutations associated with EA2 show loss-
of-function or partially functional Cav2.1 calcium channels (Jen et al., 2001). Lowered Ca
2+ 
inﬂ ux is predicted during single depolarizations as well as during repetitive neuronal activity. 
Cav2.1 channels are tightly coupled to neurotransmitter release in many neurons and medi-
ate the depolarization-induced calcium current in Purkinje cells. Reduced depolarizations in 
these neurons may possibly underlie processes that later lead to atrophy.
A brain alkalosis-driven change shifting the creatine kinase reaction towards PCr produc-
tion (PCr + ADP ⇔ Cr + ATP) may be one explanation for decreased cerebellar tCr. EA2 
patients may present with cerebellar alkalosis that normalizes under acetazolamine treat-
ment. Acetazolamide also reduces PCr/Pi and ATP/Pi ratios (Sappey-Marinier et al., 1999). 
On the other hand, the T2-relaxation difference between PCr and Cr may shift the reaction 
equilibrium and thus lead to a decreased tCr-signal in the long-TE (288ms) spectrum (Ke et 
al., 2002). This, together with a possible decrease in concentration of Cr or PCr may cause 
the tCr/H2O decrease observed. As a whole, decreased cerebellar tCr supports the hypoth-
esis of an alkalosis-driven creatine kinase-reaction shift and may reﬂ ect neurochemical 
changes in dysfunctioning Cav2.1 channels before a patient develops cerebellar atrophy 
and NAA decrease.
16. Future prospects
Over the last decade, genetic and phenotypic knowledge of EA2 and FHM has shown huge 
improvements. The mutations coding for dysfunctioning ion channels and their functional 
research has helped in understanding some of the pathogenesis of migraine and ataxia. Re-
cently, evidence has emerged on overlapping mechanisms and the etiology of EA2, FHM, 
and on the other hand, epilepsy (Jen et al., 2004, Vanmolkot et al., 2003).
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Vertigo and dizziness in migraine patients will most probably receive more emphasis in the 
future, because the deﬁ nition of migraine vertigo is becoming better clariﬁ ed (Neuhauser 
et al., 2001, Neuhauser and Lempert, 2004). Neurotologic studies have brought insight 
into the pathophysiology of migraine and conﬁ rmed the subclinical lesions in the cerebel-
lum (Kruit et al., 2004), which may broaden our view of the interconnections in migraine 
mechanisms.
Many EA2 and FHM patients still lack a proper diagnosis in which a genetic test or a bio-
marker may serve as a helpful tool. However, clinical diagnosis has a value in itself, even 
with no genetic conﬁ rmation of the disease. Most likely, more CACNA1A mutations for 
EA2 are yet to be expected. Possibly chromosomal loci other than 19p may be found, since 
not all EA2 families have been linked to this region (Jen et al., 2004). New chromosomal 
loci will probably be found in FHM as well, because some FHM families do not link to 
chromosomes 19p13 or 1q23 (Ducros et al., 1997).
Clinical research will be needed on the phenotype of migraine, FHM, and EA2. Different 
non-invasive clinical and neuroimaging techniques, in vivo physiology, and pharmacologi-
cal studies integrated with molecular genetics will have implications for the understanding 
of migraine and EA2 pathogenesis (Goadsby, 2004, Cohen and Goadsby, 2004). Functional 
studies on the consequences of disease-causing mutations will probably be of great impor-
tance. Studies on the rare types of migraine will most probably aid in the understanding of 
the more common types of migraine when one will see how the functional defects converge 
as common pathophysiological mechanisms of migraine. These efforts will eventually lead 
to better diagnostics and treatments for these disorders.
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CONCLUSIONS
The common types of migraine, familial hemiplegic migraine, and episodic ataxia type 2 
show an interesting unity, with partially shared genetic backgrounds. New scientiﬁ c data 
on the pathophysiology and genetics of these diseases is rapidly accumulating. This study 
was centered on the neurotologic abnormalities of migraine syndromes and on the other 
hand on the pathophysiology of EA2 with respect to neurotologic and metabolic changes. 
The main results and conclusions are as follows:
• The common types of migraine seemed to share similar types of neurotologic ab-
normalities that suggested mainly vestibulocerebellar dysfunction in oculomotor 
and postural control.
• In FHM2, neurotologic changes were subclinical, consistent with changes seen in 
the common types of migraine. 
• A novel mutation of the CACNA1A was identiﬁ ed in a family with EA2.
• EA2 patients showed improved baseline oculomotor and postural function while on 
acetazolamide treatment, which is a novel ﬁ nding. These results may reﬂ ect the di-
versity of dysfunctional calcium channels and conﬁ rm the action of acetazolamide 
treatment for EA2.
• EA2 patients, most of whom were nonataxic, showed decreased cerebellar total 
creatine in 1H MRS. This most probably is the ﬁ rst sign reﬂ ecting P/Q-type calcium 
channel dysfunction in Purkinje cells.
In conclusion, vestibulocerebellar changes in oculomotor and postural function were sub-
clinical in the common types of migraine and partly in EA2 patients as well. 1H MRS 
for FHM2 patients could bring novel understanding to FHM2 pathophysiology, especially 
targeted at the cerebellum. 
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